AGREEMENTVoting Agreement • June 2nd, 2006 • Innovate Oncology, Inc. • Non-operating establishments • New York
EXHIBIT 10.2 EMPLOYMENT AGREEMENT AGREEMENT dated as of May 26th, 2006, between INNOVATE ONCOLOGY, INC., a Nevada corporation ("COMPANY"), and CHRISTOPHER NOWERS, an individual ("EXECUTIVE"). Company desires to employ Executive, and Executive desires...Employment Agreement • June 2nd, 2006 • Innovate Oncology, Inc. • Non-operating establishments • California
EXHIBIT 99.1 AVANTOGEN LOGO INNOVATE ONCOLOGY LOGO AVANTOGEN AND INNOVATE COMPLETE MERGER OF KEY ONCOLOGY PROGRAM MAY 26, 2006 - Avantogen Limited ("Avantogen", ASX:ACU), Sydney, Australia and San Diego, CA, and Innovate Oncology, Inc ("Innovate";...Definitive Agreement • June 2nd, 2006 • Innovate Oncology, Inc. • Non-operating establishments
MAY 26, 2006 - Avantogen Limited ("Avantogen", ASX:ACU), Sydney, Australia and San Diego, CA, and Innovate Oncology, Inc ("Innovate"; IOVO:OTCBB), New York, closed today on the Definitive Agreement combining their oncology businesses, that was executed and announced by the companies on February 1, 2006. Pursuant to that agreement, Avantogen transferred to Innovate the 50% of Resistys, Inc., not already owned by Innovate, and as a result, Innovate will control 100% of the North American marketing rights for product sales of RP101, a promising chemoresistance inhibitor. The transaction had previously been approved by a majority of both Innovate and Avantogen shareholders.
